(Q74225012)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

J P Feighner

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

A R Entsuah

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M K McPherson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

Journal of Affective Disorders

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

1-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

55-62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Follow-up and family study of anxious depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

SSRIs in anxious-agitated depression: a post-hoc analysis of 279 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Appropriateness of drugs prescribed by primary care physicians for depressed outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Neurotic illness and its response to anxiolytic and antidepressant treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Efficacy of venlafaxine in depressive illness in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

The anxiety factor in depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Sertraline 50 mg daily: the optimal dose in the treatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

The relationship of anxiety and depression: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

Anxious depressions. Clinical, family history, and naturalistic outcome--comparisons with panic and major depressive disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-0327%2897%2900109-2

7 January 2021

10.1016/S0165-0327(97)00109-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9476744%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference